Phase 2 N=70 Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
Respiratory Syncytial Virus Infections
Primary: Area Under the Viral Load-time Curve (VL-AUC) of RSV — 0.00; 96.65 h*log10 PFU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=698 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
Clostridium Difficile Infection · Infection · Communicable Diseases
Primary: Safety and Tolerability of RBX2660 in Subjects With Recurrent CDI. — 697 Participants
N/A N=28 A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism
Autism Spectrum Disorder
Primary: Childhood Autism Rating Scale 2nd Edition (CARS2) — -7.68; -1.61 units on a scale — p=0.0002
Phase 2 N=21 Ketamine for the Treatment of Opioid Use Disorder and Depression
Depression · Opioid-use Disorder · Opioid Abuse
Primary: Percentage of Individuals Completing Informed Consent — 34 Participants
Phase 2 N=32 A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Treatment-Emergent Adverse Events — 0; 2 Adverse Events
Phase 3 N=66 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001
N/A N=23 Transcranial Magnetic Stimulation for Treatment of Insomnia
Insomnia
Primary: Pittsburgh Sleep Quality Index ( PSQI) — 12.50; 11.70; 10.37; 9.50 score on a scale
N/A N=60 Lesser Tuberosity Osteotomy for Subscapularis Repair
Osteoarthritis
Primary: Number of Subjects With Radiologic Evidence of Anatomic Healing — 26; 27 Participants
Phase 1 N=15 Brain Imaging in Tobacco Smokers During a Quit Attempt
Tobacco Use Disorder · Tobacco Smoking
Primary: Distribution Volume (VT) as Determined by [18F]-ASEM PET Scan — 22.640; 21.588; 22.226; 17.431 mL/cm^3
Phase 2 N=369 A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Change From Baseline in Pre-CAE (Controlled Adverse Environment) Ocular Discomfort Score (ODS) on a Visual Analogue Scale at Day 28 — -15.3; -11.0…
Phase 2 N=8 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Non-Small Cell Lung Cancer (NSCLC)
Primary: Objective Response Rate (ORR) in Cohort A — 33.3 percentage of participants
N/A N=146 Reducing Teen Pregnancy in the Emergency Department
Reproductive Behavior · Sexual Behavior · Adolescent Behavior
Primary: Potential Efficacy: Effective Contraception Initiation Rates [Time Frame: Enrollment, 12 Weeks Post-enrollment (2 Weeks Post Close of Intervention)] — 14; 14 Participants
Phase 3 N=706 Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Chronic Heart Failure (CHF)
Primary: Change From Baseline in the CogState Global Cognitive Composite Score (GCCS) — -0.0902; -0.0722 Global Cognitive Composite Score — p=0.7363
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
N/A N=75 CCCR Lupus Patient Navigator Program
Systemic Lupus Erythematosus (SLE)
Primary: Improvement in Quality of Life — 59.2; 63.6 score on a scale